New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
March 3, 2025, Celltrion announced the FDA approval of Stoboclo (denosumab-bmwo), biosimilar to Amgen’s Prolia® (denosumab).
Download PDF
Return to publications
